Generate robust and reliable immunohistochemistry data with PROGEN antibodies

24 Mar 2021
Edward Carter
Publishing / Media

Select from more than 400 PROGEN immunohistochemistry (IHC) antibodies, including many validated and established tissue- and tumor-specific markers for use in basic research and clinical diagnostics of a variety of cancers.

Coming from leading research groups, PROGEN´s portfolio includes markers for more than 40 pathologies in 25 organs and tissues. The antibodies are established IHC tools that have been highly published, externally validated, and tested for optimal performance in their respective application.

The monoclonal and polyclonal antibodies are commonly used for diagnostics, prognostics, and the analysis of predictive biomarkers. Some of which represent established and most commonly used antibody clones in the pathology community. The monoclonal antibodies derived from the clones keratin 20 (IT-Ks20.8), vimentin (Vim3B4), EP-CAM (HEA125), or p53 (Bp53.11) are champions in the detection of their respective proteins in a variety of applications.

To enable an optimized IHC-workflow from start to finish, PROGEN offers a selection of antibodies in sample sizes for testing as well as easy-to-use prohisto-staining kits for a more powerful detection & visualization.

Key features:

  • More than 400 monoclonal & polyclonal antibodies for IHC
  • Markers for 40 pathologies in 25 organs/tissues
  • Established and trusted IHC-tools in basic research & tumor diagnostics/prognostics
  • Validated & highly published
  • Easy establishment of IHC assays by combining PROGEN antibodies & prohisto staining kits
  • Available in sample sizes

Relevant applications:

  • Basic research of organs/tissues
  • Cancer research
  • Clinical diagnostics & prognostics, esp. tumors
  • Pathology, esp. tumors


Find out more about Progen’s antibodies here:

Links

Tags